1. Impact of co-morbidities on measuring indirect utility by the Medical Outcomes Study Short Form 6D in lower-limb osteoarthritis
- Author
-
Jacques Pouchot, Bruno Fautrel, Anne-Christine Rat, Cécile Gaujoux-Viala, K. Hosseini, Joël Coste, Francis Guillemin, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Service de Rhumatologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Centre d'Investigation Clinique INSERM 1412 (CIC 1412 - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Université de Lorraine (UL), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Maladies chroniques, santé perçue, et processus d'adaptation ( APEMAC ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Centre d'Investigation Clinique INSERM 1412 ( CIC 1412 - BREST ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Lymphocyte B et Auto-immunité ( LBAI ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), and CHRU Brest - Service de Rhumatologie ( CHU - BREST - Rhumato )
- Subjects
Male ,Multivariate statistics ,[SDV]Life Sciences [q-bio] ,MESH : Aged ,MESH: Comorbidity ,Comorbidity ,Osteoarthritis ,Severity of Illness Index ,Osteoarthritis, Hip ,MESH : Cross-Sectional Studies ,MESH: Health Surveys ,0302 clinical medicine ,Activities of Daily Living ,MESH: Osteoarthritis, Knee ,MESH : Female ,030212 general & internal medicine ,ComputingMilieux_MISCELLANEOUS ,MESH: Aged ,MESH: Middle Aged ,Psychiatric Disease ,Middle Aged ,Osteoarthritis, Knee ,[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,MESH : Comorbidity ,Female ,MESH : Severity of Illness Index ,Co morbidity ,MESH : Osteoarthritis, Hip ,medicine.medical_specialty ,WOMAC ,MESH : Male ,MESH : Health Surveys ,Lower limb ,[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,03 medical and health sciences ,MESH: Cross-Sectional Studies ,Rheumatology ,MESH: Severity of Illness Index ,Linear regression ,medicine ,Humans ,MESH : Middle Aged ,MESH : Osteoarthritis, Knee ,Aged ,030203 arthritis & rheumatology ,MESH: Humans ,[ SDV ] Life Sciences [q-bio] ,business.industry ,MESH : Humans ,MESH: Activities of Daily Living ,medicine.disease ,Health Surveys ,MESH: Male ,Cross-Sectional Studies ,Physical therapy ,Marginal impact ,MESH: Osteoarthritis, Hip ,MESH : Activities of Daily Living ,business ,MESH: Female - Abstract
International audience; Co-morbidities can influence generic measurement of health indirect utility. We investigated their impact to assess indirect utility with the Medical Outcomes Study Short Form 6D (SF-6D) in patients with osteoarthritis (OA). In patients with hip and knee OA from the Knee and Hip Osteo-Arthritis Long-term Assessment (KHOALA) study, co-morbidities were assessed by the Functional Co-morbidity Index. Multivariate linear regressions were used to determine predictors of utility score.For the 878 patients included, the mean (standard deviation (SD)) utility score for 808 patients was 0.66 (11; range 0.32-1.00) and mean number of co-morbidities 2.05 (1.58). Number of co-morbidities (beta = -0.30; p = 0.002), psychiatric disease (beta = -0.043; p < 0.0001) and degenerative disc disease (beta = -0.014; p = 0.018) were predictors of low utility score. The WOMAC functional score had a higher significant effect (beta = -0.003; p < 0.0001) and explained a higher percentage of the model variance.; For the 878 patients included, the mean (standard deviation (SD)) utility score for 808 patients was 0.66 (11; range 0.32-1.00) and mean number of co-morbidities 2.05 (1.58). Number of co-morbidities (beta = -0.30; p = 0.002), psychiatric disease (beta = -0.043; p < 0.0001) and degenerative disc disease (beta = -0.014; p = 0.018) were predictors of low utility score. The WOMAC functional score had a higher significant effect (beta = -0.003; p < 0.0001) and explained a higher percentage of the model variance.
- Published
- 2012